吡格列酮对重症急性胰腺炎血清核因子-κB的影响以及临床疗效研究

徐宝琪; 李伊倩; 陈渠发

doi:10.3969/j.issn.1671-038X.2017.05.08

吡格列酮对重症急性胰腺炎血清核因子-κB的影响以及临床疗效研究

- 东莞市第三人民医院消化内科, 广东东莞 523320

详细信息

作者简介:
徐宝琪,女,本科,主治医师,研究方向:消化系统疾病治疗

通讯作者: 徐宝琪,E-mail:13480400695@163.com

中图分类号: R576

收稿日期: 2016-12-20

The effect of pioglitazone on nuclear factor kappa B in patients with severe acute pancreatitis and its clinical efficacy

- Department of Digestive Medicine, the third People's Hospital of Dongguan, Guangdong 523320, China

More Information

Corresponding author: XU Bao-qi, E-mail: 13480400695@163.com

Received Date: 20 December 2016

摘要

摘要: [目的]观察吡格列酮对重症急性胰腺炎患者基因转录调控核因子-κB （NF-κB）信号通路以及炎症反应的影响，并评价了其临床疗效。[方法]收集2012年7月~2016年10月我院住院治疗的重症急性胰腺炎患者94例，使用信封法把所有患者分为对照组和观察组，每组47例。P65、肿瘤坏死因子α（TNF-α）、白介素-6（IL-6）使用ELISA法检测。[结果]治疗前2组P65、TNF-α和IL-6差异无统计学意义（P>0.05）。治疗后观察组P65、TNF-α和IL-6均显著低于对照组（P<0.01）。观察组的肠功能恢复时间、淀粉酶恢复时间、住院时间分别为（3.48±0.86） d、（6.05±1.53） d和（13.46±2.43） d，均显著低于对照组的（5.68±1.73） d、（9.37±2.04） d和（19.49±4.15） d （P<0.05）。观察组临床治疗有效率为89.4%（42/47）显著高于对照组的70.2%（33/47）。观察组并发症发生率为12.8%（6/47），显著低于对照组的31.9%（15/47）（P<0.05）。观察组死亡率为8.5%（4/47），显著低于对照组的19.1%（9/47）（P<0.05）。[结论]吡格列酮可以抑制重症急性胰腺炎NF-κB信号通路，减低患者炎症反应，临床疗效显著。
- 吡格列酮 /
- 重症急性胰腺炎 /
- 基因转录调控核因子-κB /
- 炎症反应
Abstract: [Objective] To detect the effect of pioglitazone on nuclear factor kappa B(NF-κB) in patients with severe acute pancreatitis and explore its clinical efficacy.[Methods] A total of 94 patients with severe acute pancreatitis who were hospitalized from July 2012 to October 2016 were enrolled in this study.All patients were divided into control group(n=47) and observation group(n=47) by envelope method.The expression of inflammatory factors(P65, TNF-α and IL6) of the pancreas was detected by ELISA.[Results] There was no significant difference in P65, TNF-α and IL-6 between the two groups before treatment(P>0.05).After treatment, P65, IL-6, and TNF-α expression were significantly lower in observation group than those in control group(P<0.01).The recovery time of intestinal function, amylase recovery time and hospitalization time of the observation group were 3.48±0.86 d, 6.05±1.53 d, and 13.46±2.43 d, which were significantly lower than those of the control group(5.68±1.73 d, 9.37±2.04 d, and 19.49±4.15 d(P<0.05).The effective rate of clinical treatment in observation group was 89.4%(42/47), which was significantly higher than that of 70.2%(33/47) in control group(P<0.05).The incidence of complication in the observation group was 12.8%(6/47), which was significantly lower than that of 31.9%(15/47) in control group(P<0.05).The mortality rate in the observation group was 8.5%(4/47), which was significantly lower than that of 19.1%(9/47) in control group(P<0.05).[Conclusion] Pioglitazone can inhibit NF-κBsignaling pathway in severe acute pancreatitis patients to reduce inflammation, with significantly clinical efficacy.
- Pioglitazone /
- severe acute pancreatitis /
- NF-κ B /
- inflammation

HTML全文

参考文献(9)

[1]	Sah R P, Dawra R K, Saluja A K.New insights into the pathogenesis of pancreatitis[J].Curr Opin Gastroenterol, 2013, 29:523-530.
[2]	Xu P, Lou X L, Chen C.Effects of peroxisome proliferator-activated receptor-γ activation on apoptosis in rats with acute pancreatitis[J].Dig Dis Sci, 2013, 58:3516-3523.
[3]	Xu P, Lou X L, Chen C.Apoptotic Mechanisms of Peroxisome Proliferator-Activated Receptor-γ Activation in Acinar Cells During Acute Pancreatitis[J].Pancreas, 2016, 45:179-186.
[4]	徐萍, 李清华, 王静, 等.吡格列酮对重症急性胰腺炎血清细胞因子和组织病理学评分的影响[J].中华临床医师杂志:电子版, 2010, 4(9):76-80.
[5]	中华医学会外科学分会胰腺外科学组.急性胰腺炎诊治指南(2014)[J].中国实用外科杂志, 2015, 35(1):4-7.
[6]	邹云良, 黎德庆, 陈建良.L-谷氨酰胺呱仑酸钠治疗重症急性胰腺炎的临床疗效研究[J].中国中西医结合消化杂志, 2015, 23(3):199-201.
[7]	颜琼, 邓明明.核因子-κB在重症急性胰腺炎肝损伤中的作用[J].广东医学, 2014, 35(4):614-616.
[8]	Li G, Wu X, Yang L, et al.TLR4-mediated NF-κB signaling pathway mediates HMGB1-induced pancreatic injury in mice with severe acute pancreatitis[J].Int J Mol Med, 2016, 37:99-107.
[9]	Kim M J, Bae G S, Jo I J, et al.Loganin protects against pancreatitis by inhibiting NF-κB activation[J].Eur J Pharmacol, 2015, 765:541-550.